section name header

Evidence summaries

Atypical Antipsychotics for People with Both Schizophrenia and Depression

There is insufficient evidence on the effects of atypical antipsychotics for people with both schizophrenia and depression Level of evidence: "D"

A Cochrane review [Abstract] 1 included 3 studies with a total of 310 subjects. One trial found no significant difference between quetiapine and haloperidol for the outcome of 'less than 50% reduction in PANSS score' (n=180, RR 0.91 CI 0.8 to 1.0). Those allocated sulpiride had significantly lower depression scores compared with people given chlorpromazine (1 RCT, n=36, WMD CPRS -0.70 CI -1.2 to -0.2). Clozapine constantly scored better on Hamilton scores than other antipsychotic drugs plus an antidepressant or placebo, (1 RCT, n=29, WMD vs antipsychotic + mianserin -5.53 CI -8.23 to -2.8; 1 RCT, n=32, WMD vs antipsychotic + meclobemide -4.35 CI -6.7 to -2.03; 1 RCT, n=33, WMD vs antipsychotic + placebo - 6.35 CI -8.6 to -4.1).

Comment: The quality of evidence is downgraded by imprecise results (limited study size for each comparison, few patients and wide confidence intervals) and by inconsistency (heterogeneity in interventions and outcomes).

References

  • Furtado VA, Srihari V. Atypical antipsychotics for people with both schizophrenia and depression. Cochrane Database Syst Rev 2008 Jan 23;(1):CD005377. [PubMed]

Primary/Secondary Keywords